Chemclin Diagnostics Co., Ltd. (688468.SS)
CNY 7.26
(0.55%)
CNY 7.26
(0.55%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 219.33 Million CNY | -5.78% |
| 2022 | 232.23 Million CNY | 6.45% |
| 2021 | 220.02 Million CNY | 21.17% |
| 2020 | 183.57 Million CNY | -10.49% |
| 2019 | 206.68 Million CNY | 153.83% |
| 2018 | -373.9 Million CNY | 2.98% |
| 2017 | -385.37 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 42.17 Million CNY | 27.87% |
| 2024 Q2 | 50.47 Million CNY | 1.17% |
| 2024 Q3 | 45.21 Million CNY | -19.64% |
| 2023 Q1 | 38.87 Million CNY | -8.08% |
| 2023 FY | - CNY | -5.78% |
| 2023 Q4 | 31.4 Million CNY | -38.57% |
| 2023 Q3 | 51.12 Million CNY | 6.01% |
| 2023 Q2 | 48.22 Million CNY | 24.05% |
| 2022 Q3 | 57.62 Million CNY | 59.7% |
| 2022 Q2 | 36.07 Million CNY | -20.09% |
| 2022 Q1 | 45.15 Million CNY | 12.86% |
| 2022 FY | - CNY | 6.45% |
| 2022 Q4 | 42.29 Million CNY | -26.6% |
| 2021 Q2 | 36.91 Million CNY | -17.84% |
| 2021 Q1 | 44.93 Million CNY | 128.05% |
| 2021 FY | - CNY | 21.17% |
| 2021 Q4 | 40 Million CNY | -7.9% |
| 2021 Q3 | 43.43 Million CNY | 17.68% |
| 2020 Q1 | 10.04 Million CNY | 105.8% |
| 2020 FY | - CNY | -10.49% |
| 2020 Q4 | -160.21 Million CNY | -211.05% |
| 2020 Q3 | 144.27 Million CNY | 434.82% |
| 2020 Q2 | 26.97 Million CNY | 168.59% |
| 2019 Q3 | 128.49 Million CNY | 0.0% |
| 2019 Q4 | -173.29 Million CNY | -234.86% |
| 2019 FY | - CNY | 153.83% |
| 2018 FY | - CNY | 2.98% |
| 2017 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 1.11 Billion CNY | 80.305% |
| Joinn Laboratories(China)Co.,Ltd. | 639.51 Million CNY | 65.702% |
| WuXi AppTec Co., Ltd. | 14.16 Billion CNY | 98.452% |
| Autobio Diagnostics Co., Ltd. | 1.87 Billion CNY | 88.288% |
| Thalys Medical Technology Group Inc. | -23.79 Million CNY | 1021.851% |
| Guangzhou Kingmed Diagnostics Group Co., Ltd. | 1.33 Billion CNY | 83.529% |